San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
CAMBRIDGE, Mass., Aug. 24, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at the following upcoming investor conferences.
- Baird 2017 Global Healthcare Conference on September 7, 2017 at 11:25 a.m. ET. The fireside chat will be held at the InterContinental New York Barclay Hotel in New York.
- Morgan Stanley 2017 Global Healthcare Conference on September 11, 2017 at 10:30 a.m. ET. The fireside chat will be held at the Grand Hyatt Hotel in New York.
- LEERINK Partners Roundtable – Rare Disease on September 27, 2017 at 10:00 a.m. ET. The fireside chat will be held at the Lotte New York Palace Hotel in New York.
The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
